The contraceptive had U.S. brand and generic sales of roughly $116.8 million, according to data from IQVIA for the 12 months ended September 2017.
Generic Drugs & Pharmacy News
Patent expirations on branded drugs are the generics industry’s bread and butter — and the years to come hold a lot of promise.
Even as more approvals roll in and industry officials talk about how biosimilars will bring significant savings in the coming decade, there is a concern that regulatory and reimbursement hurdles could prevent the industry from realizing the full savings of the less-expensive alternative to biologics.
As the generics industry squares off against price deflation, manufacturers are looking for new product areas in need of lower-cost alternatives — and recent Food and Drug Administration efforts are helping with the discovery process.
The product had brand and generic sales of roughly $53 million for the 12 months ended September 2017, according to IQVIA data.
Dr. Reddy’s said it is first to market this generic in Canada.
The launch adds to Mylan’s oncology portfolio, which it said contains more than 40 products.
The antipsychotic had U.S. sales of roughly $130 million for the 12 months ended July 31, according to QuintilesIMS data.